Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IONS |
---|---|---|
09:32 ET | 87414 | 38.795 |
09:34 ET | 144325 | 38.35 |
09:36 ET | 24820 | 38.095 |
09:38 ET | 57777 | 38.03 |
09:39 ET | 8620 | 38.52 |
09:41 ET | 14888 | 38.165 |
09:43 ET | 2210 | 38.11 |
09:45 ET | 203316 | 38.22 |
09:48 ET | 15494 | 38.39 |
09:50 ET | 728 | 38.33 |
09:52 ET | 3298 | 37.92 |
09:54 ET | 9295 | 37.72 |
09:56 ET | 6334 | 37.97 |
09:57 ET | 500 | 37.955 |
09:59 ET | 6093 | 37.965 |
10:01 ET | 7902 | 37.88 |
10:03 ET | 5352 | 37.91 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Ionis Pharmaceuticals Inc | 5.7B | -14.2x | --- |
Halozyme Therapeutics Inc | 5.8B | 19.0x | --- |
Apellis Pharmaceuticals Inc | 5.1B | -11.9x | --- |
Intra-Cellular Therapies Inc | 7.1B | -57.9x | --- |
CRISPR Therapeutics AG | 4.8B | -20.9x | --- |
ACADIA Pharmaceuticals Inc | 2.5B | -1,163.2x | --- |
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.7B |
---|---|
Revenue (TTM) | $776.6M |
Shares Outstanding | 146.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.35 |
EPS | $-2.67 |
Book Value | $2.68 |
P/E Ratio | -14.2x |
Price/Sales (TTM) | 7.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -45.47% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.